about
EGFR/HER-targeted therapeutics in ovarian cancerFlow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways.Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migrationIncreased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation.Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discoveryPalliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.Targeting signaling pathways in epithelial ovarian cancer.Intraoperative imaging in ovarian cancer: fact or fiction?A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinibHigh-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancerNanocarrier systems for delivery of siRNA to ovarian cancer tissues.Biomarkers for early detection of ovarian cancer.Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion.Conjugates of daidzein-alliinase as a targeted pro-drug enzyme system against ovarian carcinoma.
P2860
Q26863231-67293160-33F5-4685-9F14-1DA1AFCE173BQ30446755-512DD396-AF63-4A82-A4E9-328690C263A1Q33699826-ABF94DD4-589E-46DB-A59A-AE264FBF42D7Q34405324-B2EC1958-B456-417A-8F62-1DD8B721C0D8Q34478979-0F008283-B8C9-4719-B9BF-B6A7A890300DQ35767493-8E2B86F6-3A49-4DEE-93DD-5A18384D9EE7Q35837949-83182533-A858-4FA6-926D-EF96AB05210BQ35847701-305FCB1E-0464-4FFF-BD65-563D230E70AEQ35879981-1891BB4A-6A8B-4EB0-BD57-9C2511405CA3Q35911242-9999FC47-0AAD-43C6-86BD-CA07AF2132D0Q36440499-E17DE454-7DB1-4C24-9F3D-BDFCE854E266Q36596826-941D19D8-26B6-456B-862C-43BD05A43570Q36648394-7831D5EB-F751-478E-819E-49A9D42F23D1Q36790826-CC532719-3DC3-45D0-86BE-8CFB21E66EE4Q36913614-DEA624C9-13FD-4AB2-973B-CA4AC6BB4380Q37149571-8367D06C-4C9F-46DC-8CEA-2D794B17BC5CQ37205345-F8EB6569-A074-4F9C-921B-089B3F43897CQ37283860-B9741181-9298-41BE-A9A1-2F4854E14B68Q37459590-8280C861-8116-414C-A8D8-D5783021A4FBQ38015511-F44EF1D4-61BA-4888-BF9D-7BCAAFA43E2FQ38087982-058E4FF5-A31E-4994-9327-83FF3ACADF4BQ38926129-3B7ADE4F-5FC8-4FB1-AAE2-A68497453567Q39672715-9A075FD3-D576-40D8-BE2E-D245A2DCC188
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeting the EGF receptor for ovarian cancer therapy.
@ast
Targeting the EGF receptor for ovarian cancer therapy.
@en
Targeting the EGF receptor for ovarian cancer therapy.
@nl
type
label
Targeting the EGF receptor for ovarian cancer therapy.
@ast
Targeting the EGF receptor for ovarian cancer therapy.
@en
Targeting the EGF receptor for ovarian cancer therapy.
@nl
altLabel
Targeting the EGF receptor for ovarian cancer therapy
@en
prefLabel
Targeting the EGF receptor for ovarian cancer therapy.
@ast
Targeting the EGF receptor for ovarian cancer therapy.
@en
Targeting the EGF receptor for ovarian cancer therapy.
@nl
P2860
P356
P1433
P1476
Targeting the EGF receptor for ovarian cancer therapy.
@en
P2093
Laurie G Hudson
M Sharon Stack
P2860
P304
P356
10.1155/2010/414676
P407
P577
2009-12-28T00:00:00Z